{
    "clinical_study": {
        "@rank": "26864", 
        "arm_group": [
            {
                "arm_group_label": "AMG 334 Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "AMG 334 Dose 1 (SC)"
            }, 
            {
                "arm_group_label": "AMG 334 Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "AMG 334 Dose 2 (SC)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo -(SC)"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly\n      migraine days"
        }, 
        "brief_title": "A Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Treatment for Prevention of Chronic Migraine", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "detailed_description": {
            "textblock": "Phase 2, multicenter, randomized, double-blind, placebo-controlled study of patients with\n      chronic migraine. Approximately 490 subjects will be randomized 3:2:2 to receive either\n      placebo, AMG 334 subcutaneous (SC) every month for the duration of the12-week double-blind\n      treatment phase. There will also be a 12-week safety follow-up (16 weeks ) after the last\n      dose of investigational product)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  History of at least 5 attacks of migraine without aura and/or migraine with visual\n             sensory, speech and/or language, retinal or brainstem aura according to the IHS\n             Classification ICHD-III\n\n          -  History of \u2265 15 headache days per month of which \u2265 8 headache days were assessed by\n             the subject as migraine days per month in each of the 3 months prior to screening\n\n          -  Demonstrated at least 80% compliance with the eDiary during baseline phase\n\n        Exclusion Criteria:\n\n          -  History of cluster headache or basilar or hemiplegic migraine headache\n\n          -  Unable to differentiate migraine from other headaches\n\n          -  Failed > 3 medication categories due to lack of efficacy for prophylactic treatment\n             of migraine after an adequate therapeutic trialFailed > 2 medication categories due\n             to lack of efficacy for prophylactic treatment of migraine after an adequate\n             therapeutic trial\n\n          -  Receive botox in head or neck region within 4 months prior to screening.\n\n          -  Used a prohibited migraine prophylactic medication, device or procedure within 2\n             months prior to the start of the baseline phase"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "490", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066415", 
            "org_study_id": "20120295"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "AMG 334 Dose 1", 
                    "AMG 334 Dose 2", 
                    "Placebo"
                ], 
                "description": "Investigational Product", 
                "intervention_name": "AMG 334", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo Comparator", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Chronic Migraine", 
        "lastchanged_date": "February 17, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention", 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Health and Medicines Authority", 
                "Germany: Paul-Ehrlich-Institut", 
                "Finland: Finnish Medicines Agency", 
                "Norway: Norwegian Medicines Agency", 
                "Sweden: Medical Products Agency", 
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in monthly migraine days from baseline in the last 4 weeks of the 12-week double-blind treatment phase. To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly migraine days, in subjects with chronic migraine", 
            "safety_issue": "No", 
            "time_frame": "Completion of double-blind treatment phase at 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066415"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of subjects with at least a 50% reduction from baseline in monthly migraine days in the last 4 weeks of the 12-week double-blind treatment phase", 
                "measure": "To evaluate the efficacy profile of AMG 334", 
                "safety_issue": "No", 
                "time_frame": "Completion of double-blind treatment phase at 12 weeks"
            }, 
            {
                "measure": "Change in monthly migraine attacks from baseline to the last 4 weeks of the 12-week", 
                "safety_issue": "Yes", 
                "time_frame": "Completion of double-blind treatment phase at 12 weeks"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}